Published in Br J Clin Pharmacol on October 01, 1993
HIV screening in 'healthy' volunteers and Ethics Committees. Br J Clin Pharmacol (1994) 0.98
A retrospective analysis of the prevalence of HIV seropositivity and its demographics in the normal healthy volunteer population of a phase-I clinical drug study unit. Br J Clin Pharmacol (1995) 0.75
HIV screening in healthy volunteers. Br J Clin Pharmacol (1995) 0.75
A testing time for doctors: counselling patients before an HIV test. BMJ (1991) 5.14
Life insurance and HIV antibody testing. BMJ (1992) 3.87
Doctors, patients, and HIV. BMJ (1992) 2.34
Heterosexual spread of human immunodeficiency virus in Edinburgh. Br Med J (Clin Res Ed) (1988) 2.15
Pre-HIV antibody testing--too much fuss? Genitourin Med (1992) 1.41
AIDS in Edinburgh drug users: observations on the epidemic and implications for its future management. J Infect (1991) 1.01
Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens (1998) 4.94
Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet (1994) 4.90
Differential dynamics of alpha 5 integrin, paxillin, and alpha-actinin during formation and disassembly of adhesions in migrating cells. J Cell Biol (2001) 3.99
The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol (2000) 3.43
Core content of a course in clinical pharmacology. Br J Clin Pharmacol (1997) 2.99
Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed) (1983) 2.90
Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation (2000) 2.83
Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens (1993) 2.59
Ultrasonic hydrophone based on short in-fiber bragg gratings. Appl Opt (1998) 2.35
Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol (1999) 2.35
The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) (1993) 2.18
Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol (2001) 1.97
Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM (2000) 1.84
Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation (1999) 1.79
Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol (2001) 1.77
Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol (1989) 1.68
Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci (Lond) (2003) 1.66
Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest (1997) 1.65
Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens (1999) 1.62
Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 1.61
L-NMMA increases blood pressure in man. Lancet (1993) 1.60
Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study. BMJ (1998) 1.60
Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) (2001) 1.59
Developing a core curriculum in clinical pharmacology and therapeutics: a Delphi study. Br J Clin Pharmacol (1997) 1.58
Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci (2001) 1.52
Microvascular correlates of blood pressure, plasma glucose, and insulin resistance in health. Cardiovasc Res (2002) 1.51
Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens (1998) 1.48
Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation (1996) 1.47
32-km distributed temperature sensor based on Brillouin loss in an optical fiber. Opt Lett (1993) 1.46
Aortic pulse-wave velocity. Lancet (1999) 1.45
Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation (1999) 1.44
Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res (2000) 1.43
Effects of leptin on insulin sensitivity in normal rats. Endocrinology (1997) 1.42
Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens (1999) 1.42
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol (2007) 1.38
Transversal and longitudinal images from the retina of the living eye using low coherence reflectometry. J Biomed Opt (1998) 1.36
Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology (2006) 1.34
Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation (2001) 1.32
Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol (1989) 1.32
Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation (1995) 1.31
Use of anorectal manometry during rectal infusion of saline to investigate sphincter function in incontinent patients. Gastroenterology (1983) 1.31
Blood glucose monitors: a laboratory and patient assessment. Br Med J (1980) 1.30
Ano-rectal activity in man during rectal infusion of saline: a dynamic assessment of the anal continence mechanism. J Physiol (1982) 1.29
Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide. Clin Sci (Lond) (1997) 1.27
Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart (2005) 1.26
Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med (2002) 1.24
Direct measurement of intracellular pH changes in Xenopus eggs at fertilization and cleavage. J Cell Biol (1981) 1.23
Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 1.21
Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol (1998) 1.21
Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab (1995) 1.19
Measurement of plasma angiotensin II. Clin Sci (Lond) (1985) 1.19
31P NMR reveals increased intracellular pH after fertilization in Xenopus eggs. Proc Natl Acad Sci U S A (1981) 1.18
An electrical block is required to prevent polyspermy in eggs fertilized by natural mating of Xenopus laevis. Dev Biol (1982) 1.18
Simultaneous en-face imaging of two layers in the human retina by low-coherence reflectometry. Opt Lett (1997) 1.17
Pulse transit time measured from the ECG: an unreliable marker of beat-to-beat blood pressure. J Appl Physiol (1985) (2005) 1.16
Peripheral endothelial dysfunction in normal pressure glaucoma. Invest Ophthalmol Vis Sci (1999) 1.16
Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun (2000) 1.16
Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology (2000) 1.14
The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther (1996) 1.12
Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation (1998) 1.11
Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation (1996) 1.11
Classification of alpha 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions. J Biol Chem (1994) 1.11
Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol (2001) 1.08
Scottish Medicines Consortium: an overview of rapid new drug assessment in Scotland. Scott Med J (2007) 1.08
Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens (2000) 1.07
Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol (2001) 1.05
Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc Res (1998) 1.04
Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut (2003) 1.04
Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation (2000) 1.03
Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharmacol (1997) 1.03
Fertilization potential and electrical properties of the Xenopus laevis egg. Dev Biol (1985) 1.02
Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. Br J Clin Pharmacol (1998) 1.02
Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology (2001) 1.01
Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart (2004) 1.01
Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol (1997) 1.01
Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM (2009) 1.00
An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost (1997) 1.00
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation (1998) 0.99
Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation (1991) 0.99
Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension (1998) 0.99
Forearm vasoconstriction to endothelin-1 is mediated by ETA and ETB receptors in vivo in humans. J Cardiovasc Pharmacol (1995) 0.98
State-of-the-art-lecture: Obesity-induced hypertension: new concepts from the emerging biology of obesity. Hypertension (1999) 0.98
Coherence imaging by use of a Newton rings sampling function. Opt Lett (1996) 0.98
Frequency response characteristics of sympathetically mediated vasomotor waves in humans. Am J Physiol (1998) 0.97
S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol (2000) 0.97
Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes: the EURODIAB Complications Study. Diabetes Care (2001) 0.96
Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia (2007) 0.96
Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation (1996) 0.95
Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation (2001) 0.95
Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart (1996) 0.94
Ultrasound findings in renal parenchymal disease: comparison with histological appearances. Clin Radiol (1994) 0.94
Alpha 2-macroglobulin and the alpha 2-macroglobulin receptor/LRP. A growth regulatory axis. Ann N Y Acad Sci (1994) 0.93
The Trevor Howell Lecture. Age, arterial stiffness and the endothelium. Age Ageing (1997) 0.93
Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int (1998) 0.93
The effects of short-term passive smoke exposure on endothelium-dependent and independent vasodilation. J Hypertens (1999) 0.93